Welcome, Guest
Username: Password: Remember me
General
  • Page:
  • 1

TOPIC: Cytori Obtains Celution® Approval in Singapore

Cytori Obtains Celution® Approval in Singapore 07 Oct 2013 07:22 #933

  • keysman
  • keysman's Avatar Topic Author
  • Offline
  • Junior Boarder
  • Junior Boarder
  • Posts: 22
  • Thank you received: 4
Cytori Obtains Celution® System Approval in Singapore



10/07/2013




SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (NASDAQ:CYTX) has received approval from the Health Sciences Authority (HSA) in Singapore for the Celution® System for autologous re-implantation or re-infusion of a patient’s own adipose-derived regenerative cells (ADRCs). The Celution® System enables access to a patient’s own ADRCs at the point-of-care for a range of injuries and conditions.

“Celution® System approval and claims in Singapore complements our existing Asia-Pacific approvals by strengthening market access in the region and reinforcing our global regulatory strategy. We anticipate seeing a relevant impact on sales in 2014 as a result of the approval in Singapore, combined with recent approvals and registrations in Australia, New Zealand and in Japan,” said Seijiro Shirahama, President of Asia-Pacific for Cytori. “We will continue to pursue new regulatory approvals in large markets and strategic countries in Asia as well as continue to expand existing claims for the Celution® System in the more than 40 countries where we already have approval.”

Asia-Pacific has been and continues to be a key region for Cytori, supported by a growing number of regulatory approvals and patents issued. In 2007 and 2008, Cytori received patents in Singapore covering the Celution® System and for vascular conditions relating to the use of ADRCs to restore blood flow.

Singapore represents a major medical market and is a leader in medical innovation and research, being ranked fourth in global healthcare infrastructure in the IMD World Competitiveness Yearbook in 2010. Singapore has committed more than $12 billion in continued support of research, innovation and enterprise activities between 2011 and 2015, $2.9 billion of which is dedicated to the biomedical space.

About Adipose Tissue & ADRCs

Adipose tissue is considered the richest source of regenerative cells in the body. These cells are comprised of a heterogeneous population of cells which are collectively referred to as ADRCs. The heterogeneous nature of ADRCs are believed to contribute to the healing process via multiple mechanisms, which include cell-to-cell signaling, supporting improved blood flow and regulation of the inflammatory response.

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple “ischemic” conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori’s proprietary technologies and products, including the Celution System product family. www.cytori.com

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, a sales impact in 2014 from recent regulatory approvals and obtaining and expanding current Celution® approvals are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include the challenges inherent in convincing physicians and patients to adopt the new technology as well as our history of operating losses, regulatory uncertainties, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" section in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.





Source: Cytori Therapeutics


Cytori Therapeutics

Megan McCormick, 1-858-875-5279

This email address is being protected from spambots. You need JavaScript enabled to view it.

Please Log in or Create an account to join the conversation.

Cytori Obtains Celution® Approval in Singapore 07 Oct 2013 11:40 #936

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3299
  • Thank you received: 1110
Personally I hate these non-explanatory announcements. Whether its approval in Russia, Australia or Singapore- its always states-

for autologous re-implantation or re-infusion of a patient’s own adipose-derived regenerative cells (ADRCs). The Celution® System enables access to a patient’s own ADRCs at the point-of-care for a range of injuries and conditions.


Basically it can mean a whole range of things- do not expect Cytori to explain what it means this time though. :evil: :bash:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Cytori Obtains Celution® Approval in Singapore 08 Oct 2013 07:41 #937

  • rongside
  • rongside's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 379
  • Thank you received: 196
Fas, you are very correct about the vagueness of the PR. I have sent the following e-mail to Megan but am not too hopeful of a reply....... still if you do not ask you shall not receive ...........


Dear Megan,

In your latest Press Release concerning the Celution approval in Singapore you state that, "The Celution® System enables access to a patient’s own ADRCs at the point-of-care for a range of injuries and conditions."

This is already known and does not constitute information that most investors find of use. Perhaps you could provide more color by advising us of whether the approval was for investigator use only, or for clinical use by doctors for specific indications? If for specific indications we would be most appreciative if you would list them and also provide the trial data which backed these approvals.

The above request I feel constitutes a minimum amount of information that an investor in Cytori should be entitled to, and not have to request.

If you are not in a position to provide the information I would appreciate your passing on this request to the powers that be. For your, and management's information please be advised that I have consistently held shares since shortly after the Macropore IPO and have added at regular intervals. As such my allegiance to the efforts of Cytori in the field of regenerative medicine is I feel proven. I would appreciate a similar show of allegiance from management by their providing what is I believe a reasonable request for information.

Yours sincerely,
xxxxxxxxxxxxxx
The following user(s) said Thank You: Joncon63, joeycav11, keysman

Please Log in or Create an account to join the conversation.

Cytori Obtains Celution® Approval in Singapore 08 Oct 2013 08:30 #938

  • myownhedgefund
  • myownhedgefund's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 2769
  • Thank you received: 199
Thanks for your efforts rongside and I wish you luck...I believe you will need it ! :really:

Please Log in or Create an account to join the conversation.

Cytori Obtains Celution® Approval in Singapore 08 Oct 2013 09:33 #939

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3299
  • Thank you received: 1110
Good stuff John.

Please let us know when you get an answer- if you do not I will try my luck also with the same text, since we basically have been involved for the same time span.



(Go A´s) :winky:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Cytori Obtains Celution® Approval in Singapore 08 Oct 2013 09:41 #940

  • joeycav11
  • joeycav11's Avatar
  • Offline
  • Expert Boarder
  • Expert Boarder
  • Posts: 130
  • Thank you received: 41
I am writing her also as we speak.
I

Please Log in or Create an account to join the conversation.

  • Page:
  • 1
Time to create page: 0.120 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites